CA2475454A1 - Aryl-n-cyanoguanidines and methods related thereto - Google Patents

Aryl-n-cyanoguanidines and methods related thereto Download PDF

Info

Publication number
CA2475454A1
CA2475454A1 CA002475454A CA2475454A CA2475454A1 CA 2475454 A1 CA2475454 A1 CA 2475454A1 CA 002475454 A CA002475454 A CA 002475454A CA 2475454 A CA2475454 A CA 2475454A CA 2475454 A1 CA2475454 A1 CA 2475454A1
Authority
CA
Canada
Prior art keywords
mitochondria
substituted
compound
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002475454A
Other languages
English (en)
French (fr)
Inventor
Soumitra S. Ghosh
Tomas R. Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2475454A1 publication Critical patent/CA2475454A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
CA002475454A 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto Abandoned CA2475454A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27236801P 2001-02-27 2001-02-27
US60/272,368 2001-02-27
PCT/US2002/006717 WO2002068381A2 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Publications (1)

Publication Number Publication Date
CA2475454A1 true CA2475454A1 (en) 2002-09-06

Family

ID=23039505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002475454A Abandoned CA2475454A1 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Country Status (9)

Country Link
US (4) US6562821B2 (https=)
EP (1) EP1377282B1 (https=)
JP (1) JP2004525906A (https=)
AT (1) ATE336237T1 (https=)
AU (1) AU2002254124A1 (https=)
CA (1) CA2475454A1 (https=)
DE (1) DE60213958T2 (https=)
ES (1) ES2271247T3 (https=)
WO (1) WO2002068381A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung
US7411000B2 (en) * 2001-03-15 2008-08-12 The Scripps Research Institute Process of inhibiting cell death in injured cartilage
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
US7642092B2 (en) * 2003-03-03 2010-01-05 Technion Research & Development Foundation Ltd. Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
EP3747449A4 (en) * 2018-02-02 2021-10-20 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION WITH ISOLATED MITOCHONDRIA FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265905A (en) 1975-09-30 1981-05-05 Merck & Co., Inc. Method of treating inflammation employing acyl cyanoguanidines
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
CN1450999A (zh) * 2000-03-31 2003-10-22 辉瑞产品公司 新的哌嗪衍生物
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung

Also Published As

Publication number Publication date
US20040067987A1 (en) 2004-04-08
ES2271247T3 (es) 2007-04-16
US20030045556A1 (en) 2003-03-06
DE60213958T2 (de) 2007-08-30
EP1377282B1 (en) 2006-08-16
WO2002068381A2 (en) 2002-09-06
US7230132B2 (en) 2007-06-12
ATE336237T1 (de) 2006-09-15
US6562821B2 (en) 2003-05-13
DE60213958D1 (de) 2006-09-28
AU2002254124A1 (en) 2002-09-12
EP1377282A2 (en) 2004-01-07
WO2002068381A3 (en) 2002-10-31
JP2004525906A (ja) 2004-08-26
US6927218B2 (en) 2005-08-09
US20050182057A1 (en) 2005-08-18
US20080032981A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US6268398B1 (en) Compounds and methods for treating mitochondria-associated diseases
KR0178543B1 (ko) N,n'-이치환된 구아니딘과 흥분유발 아미노산 길항제로서 그 사용방법
US6498191B2 (en) Mitochondria protecting agents for treating mitochondria associated diseases
CA2117592A1 (en) N,n'-disubstituted guanidines and their use as excitatory amino acid antagonists
MXPA04001153A (es) Derivados de amidina para tratar la amiloidosis.
EP1653943B3 (en) Catechol derivatives for the treatment of cancer
AU2013329171A1 (en) Multifunctional radical quenchers
US20080032981A1 (en) Aryl n-cyanoguanidines and methods related thereto
EP0217287A2 (en) [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7-yl)-oxy]ethanimidamides and [(2,3,9,9a-tetrahydro-3-oxo-9a-substituted-1H-fluoren-7yl)oxy]ethanimidic acid hydrazides, their derivatives and their salts
EP1100484A1 (en) Macrophage scavenger receptor antagonists
CA2488493A1 (en) Amidine derivatives for treating amyloidosis
US9463195B2 (en) Dissolution of amyloid fibrils by flavonoids and other compounds
US4782073A (en) Amides of [(5,6-dichloro-3-oxo-9-alpha-substituted-2,3,9,9-alpha-tetrahydrofluoren-7-yl-oxyl]acetic acids, and pharmaceutical compositions thereof
EP1366021B1 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
US6251898B1 (en) Medical use of fluorenone derivatives for treating and preventing brain and spinal injury
WO2013019655A2 (en) Vimentin as a biomarker for the progression of myeloproliferative neoplasms
EP2694519A1 (en) Novel heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
WO2002048092A2 (en) Compounds for altering mitochondrial function and cellular responses
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
EP1222920A2 (en) Mitochondria protecting agents for treating mitochondria associated diseases
WO2012139001A2 (en) Kinase protein binding inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued